<div><div></div><div><span><p><span>Immuneering Corp reported first-quarter 2026 results showing a narrower comprehensive loss versus the prior year, with comprehensive loss of ($13.78M) and net loss of ($13.46M), or ($0.21) per diluted share.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>($13.78M)</span></td><td><span>($15.05M)</span></td><td><span>8.4%</span></td></tr><tr><td><span>Net income²</span></td><td><span>($13.46M)</span></td><td><span>($15.05M)</span></td><td><span>10.5%</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($0.21)</span></td><td><span>($0.42)</span></td><td><span>50%</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Comprehensive Loss”. ² Reported as “Net loss”. ³ Reported as “loss per share attributable to common stockholders, basic and diluted”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Clinical progress: Initiated Phase 3 MAPKeeper 301 for atebimetinib in first-line metastatic pancreatic ductal adenocarcinoma (PDAC); first patient dosing expected mid‑2026.</span></li><li><span>Pipeline focus shift: Company prioritized atebimetinib over envometinib and cut envometinib spending by roughly 99% to reallocate resources.</span></li><li><span>Data &amp; differentiation: Positive Phase 2a interim safety/response and ctDNA data support the DCI hypothesis and potential reduced resistance.</span></li><li><span>Operational capacity: Integrated BioArkive to support internal preclinical work, expanded R&amp;D headcount and increased preclinical spending.</span></li><li><span>Funding runway: Cash resources are expected to fund operations into 2029, supporting ongoing clinical advancement and trial execution.</span></li></ul><p><span>Original SEC Filing: </span>Immuneering Corp [ IMRX ] - 10-Q - May. 15, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

IMRX

LABU

ARKG

<p>Immuneering Corp reported Q1 2026 results with revenue of $13.78M and a net income of $13.46M, showing improvements from the previous year. The company initiated Phase 3 trials for atebimetinib in pancreatic cancer and shifted focus from envometinib, cutting its spending significantly. Cash resources are projected to support operations until 2029.</p>

TradingView

Immuneering

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary